GlobeNewswire·Jul 21, 2026, 8:00 AM ET

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

Verrica Pharmaceuticals Inc. announced an exclusive distribution, marketing & supply agreement with Medomie Pharma Ltd. to seek regulatory approval & distribute YCANTH for molluscum contagiosum in Israel.
Verrica will manufacture YCANTH & provide commercial supply to Medomie, receiving 60% of the net selling price for product sold in Israel.
Verrica is eligible to receive up to $8.2 million in total regulatory & commercial milestones under the Agreement.
Verrica maintains exclusive global rights to YCANTH for all indications outside of Japan & Israel.
YCANTH is a proprietary drug-device combination product containing cantharidin & is the first & only FDA-approved healthcare professional-administered treatment for molluscum in patients aged two years & older.
US approval for YCANTH was based on two Phase 3 clinical trials involving approximately 500 patients demonstrating safety & efficacy.
YCANTH is already approved for molluscum treatment in Japan based on an additional Phase 3 trial of approximately 300 patients.
YCANTH is currently being studied in a global Phase 3 program for the treatment of common warts in the US & Japan.
Approximately six million people in the US are affected by molluscum contagiosum, primarily children, with an estimated 250 million lives eligible for insurance coverage.